Specialty Pharmacy

Ocrelizumab (Ocrevus) granted FDA approval to treat 2 forms of MS.

Novel test demonstrates the benefits of exercise in individuals with neurological injuries and illnesses.

New tuberculosis cases have declined over the past 5 years, but new data show rates are up for TB/HIV coinfections.

Eric Peacock, co-founder and CEO of MyHealthTeams, discusses the importance of specialty pharmacies collaborating with patients in their care.

Neurologist Michael Racke, MD, discusses the new FDA approval of ocrelizumab and how it will impact the future treatment of MS.

Injection helps clear skin and manage itch severity caused by the disease.

More than 3000 patients with breast cancer have received radiation with the Xoft System.

Treatment with endostatin slowed the proliferation of resistant prostate cancer cells.

Eculizumab (Soliris) can reduce disease burden for patients with refractory generalized myasthenia gravis.

Epalrestat could prevent metastasis in patients with basal-like triple-negative breast cancer.

High consumption of isoflavones reduced all-cause mortality in patients with breast cancer by 21%.

Marc O'Connor, COO and Chief Strategy Officer at Curant Health, discusses how specialty pharmacy can help patients manage high out of pocket costs for specialty drugs.

Niraparib (Zejula) FDA approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers.

There is little room for error in the highly competitive specialty pharmacy landscape.

Findings open the door for new therapeutic options for myelin regeneration in multiple sclerosis.

Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.

New report reveals trends in the 8 major markets over the next decade.

Top news of the day from across the health care landscape.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses how biosimilars could impact specialty pharmacy into the immediate future.

Pharmacists can address barriers to treatment, engage with patients, and advocate for change at the community and federal levels.

Top articles of the week from The American Journal of Pharmacy Benefits.

Top news of the week in oncology and cancer drug development.

Checkpoint inhibitors plus myeloid-derived suppressor cell inhibitors show promise as prostate cancer treatment.

Quiescent stem cells are dormant and are not impacted by cancer treatments.

Top five most popular articles this week on Specialty Pharmacy Times.

Grant E. Knowles, PharmD, vice president of Business Development at Ardon Health, discusses the potential impact of value-based care on specialty pharmacy.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival in patients with breast cancer.

Study suggests Medicare reform to help patients predict monthly medication costs.